Guggenheim took its Sage Therapeutics Inc. [NASDAQ:SAGE] rating to the equivalent of Buy from Neutral, in a research note dated January 4, 2021. Other analysts also revised their coverage, with Mizuho’s analysts upgrading the shares from “a Neutral” rating to “a Buy” rating in a research note to investors issued in early December. Meanwhile, Raymond James had lowered its rating on SAGE to ”Mkt perform” from the earlier “an Outperform”, in a research note produced for clients December 01, 2020. In addition, there was a downgrade from Morgan Stanley on November 16, 2020. The rater changed SAGE from “an Overweight” to “an Equal-weight”.
Is Sage Therapeutics Inc. [NASDAQ:SAGE] a Good Buy Right Now?
It should be noted that SAGE technical indicators for short, intermediate as well as long term progress have placed an overall average of 100% as Buy. The average signal changed from 100% Buy in the last week and compares with 88% Buy in the past month. Data from Sage Therapeutics Inc.’s Trend Spotter indicated that the signals were Weakest. The stock current average is 0.65 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 0.72 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.7 million shares.
SAGE Price Performance
On Wall Street, Sage Therapeutics Inc. [NASDAQ:SAGE] finished Thursday’s session down -2.42% at $86.51. The stock went up to $89.16 at the same session while its lowest single day price was $86.25. In the last five days, it saw a fall of about -2.45%, Sage Therapeutics Inc. shares gained by almost 19.84% since the beginning of the year. However, the share price has dropped to as low as -4.49% below its one year high. On 12/28/20, the company shares recorded $90.58, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 03/18/20, the same year at $25.01. The company’s shares have inclined by 18.25% in the past year. The 50-day SMA achieved is $76.25 while the 200-day SMA is $52.54. Volume dropped to 0.29 million from 0.34 million in the previous session.
SAGE Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 85.45 level, and in case of violation of this particular level, it will cause more drop to 84.40 level. On the upper level, 90.22 is still the key resistance. The stock may increase to the subsequent resistance at 88.36. The Relative Strength Index (RSI) pinned on the 14-day chart is 64.36, implying a neutral technical stance while the MACD stands at 5.70, meaning price will increase in the next trading period. Percent R indicator moved to 18.03%, implying bullish price movement. Stochastic %K at 86.10% suggest selling the stock.
What is the short interest in Sage Therapeutics Inc.?
Short interest in the Sage Therapeutics Inc. stock has surged, increasing by 40000.0 shares to total 5.31 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 5.35 million, data from Yahoo Finance shows. The decrease of -0.75% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 14.10% of the overall float for the stock.
Sage Therapeutics Inc.’s Biggest Shareholders: Who Owns Sage Therapeutics Inc. [SAGE]?
Filings by Fidelity Management & Research Co showed that the firm now holds a total of 7,732,540 shares or roughly 14.86% of the outstanding SAGE shares. This means their shares have increased by 8,468 from the 7,732,540 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, The Vanguard Group, Inc. updated stake is worth $329,515,942. Details in the latest 13F filings reveal that T. Rowe Price Associates, Inc. disposed off their -9.22% stake valued at $189,598,829 while D. E. Shaw & Co. LP added theirs at $182,488,560. During the last quarter, T. Rowe Price Associates, Inc. liquidated -260,018 of its shares in Sage Therapeutics Inc. while D. E. Shaw & Co. LP bought 340,910 shares. The BlackRock Fund Advisors’s holdings currently number 2,372,497 shares at $205244715.47. According to the firm’s last 13F report, Great Point Partners LLC shares in the company at filing stood at 1,966,688 shares, roughly $145,711,914.
SAGE Earnings Forecast For The Current Quarter
Sage Therapeutics Inc. [SAGE] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $55.34M and an earnings per share of -$0.45 for Dec 2020. Looking further ahead, the company is expected to report revenue of $174.85M at an EPS of $0.91 for Mar 2021. The estimates represent upside of 311.40% and 60.40% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
SAGE Earnings Estimates For The Current Year
For the financial year, Sage Therapeutics Inc. [NASDAQ:SAGE] is expected to bring in revenue of $57.75M. The returns are nearly $50.88 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -7.39, higher than that of FY19 by $5.99. Estimates put this year’s earnings growth at 44.80%, 60.40% for the next, and at an annual 41.40% over the next 5-year period. As for sales, forecasts are for an increase of 740.90% in the current fiscal year and a further 311.40% over the following year.